Connection
Jane Reusch to Drug Administration Schedule
This is a "connection" page, showing publications Jane Reusch has written about Drug Administration Schedule.
|
|
Connection Strength |
|
|
|
|
|
0.130 |
|
|
|
-
Reusch J, Stewart MW, Perkins CM, Cirkel DT, Ye J, Perry CR, Reinhardt RR, Bode BW. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab. 2014 Dec; 16(12):1257-64.
Score: 0.108
-
Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009 Oct; 32(10):1880-6.
Score: 0.019
-
Roemeling RV, Olshefski R, Langevin T, Berestka J, Reusch JJ, Reusch JE, Lakatua D, Wick MR, Hrushesky WJ. Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences. Chronobiol Int. 1986; 3(1):55-64.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|